Minerva Neurosciences | NERV - Loan Capital


Minerva Neurosciences reported $0 in Loan Capital for its fiscal quarter ending in September of 2024.





Loan Capital Change Date
Acadia Pharmaceuticals USD 0 0 Mar/2025
Adma Biologics USD 69.33M 750K Dec/2025
ALKERMES USD 285.82M 639K Sep/2024
Alterity Therapeutics Limited AUD 43.68K 59.53K Dec/2025
AstraZeneca USD 25.96B 177M Mar/2026
BioCryst Pharmaceuticals USD 428.67M 234.31M Dec/2025
Bristol-Myers Squibb USD 42.15B 698M Mar/2026
Cipla INR 2.98B 454.6M Sep/2025
Clal Biotechnology ILS 25.96M 18.48M Dec/2023
Compugen USD 0 0 Dec/2024
CSL USD 10.42B 273M Dec/2025
Eli Lilly USD 39.37B 1.5B Mar/2026
Esperion Therapeutics USD 457.65M 9.5M Dec/2025
GlaxoSmithKline GBP 14.01B 696M Mar/2026
Grifols EUR 9.95B 722.93M Dec/2025
Halozyme Therapeutics USD 2.14B 1.34B Dec/2025
Ionis Pharmaceuticals USD 1.91B 9M Mar/2026
J&J USD 37.53B 1.91B Mar/2026
Merck USD 46.67B 77M Mar/2026
Minerva Neurosciences USD 0 86.58M Sep/2024
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Novartis USD 37.45B 7.86B Mar/2026
Novavax USD 246.3M 200K Dec/2025
Pfizer USD 60.57B 1.08B Mar/2026
Roche Holding CHF 27.43B 966M Dec/2025
Sanofi EUR 13.84B 1.88B Mar/2026
Takeda JPY 4.27T 81.29B Dec/2025
Vanda Pharmaceuticals USD 3.15M 3.15M Dec/2024